Barclays upgrades Phathom Pharmaceuticals stock rating on revenue outlook By Investing.com

Barclays upgraded Phathom Pharmaceuticals to Overweight and raised its price target to $18 (from $16); the stock trades at $10.79 versus InvestingPro fair value $11.88. Q4 2025 revenue of $57.6M topped the ~$54M consensus and EPS was -$0.08 vs -$0.42 expected, while fiscal 2026 revenue guidance was raised to $320M–$345M (above ~$314M consensus). Guggenheim and Stifel also raised/maintained bullish price targets ($25 and $28), supported by 87% gross margin, 217% y/y revenue growth, narrowed non-GAAP op ex, and a strengthened balance sheet after January financing.

Analysis

A sustained uptick in weekly prescriptions is the most credible near-term growth signal and will magnify second-order winners: data vendors (IQV) that front-run script visibility, contract manufacturers that must scale production quickly, and small-cap specialty sales outfits that reallocate reps into gastroenterology. If weekly script growth proves durable over two-to-four quarters it will shift PHAT from a momentum story into a multiple-expansion story because operating leverage on a high gross-margin product converts revenue beats cleanly to free cash flow.

Key risks are concentrated and timing-driven. The next few weeks of IQVIA releases and the upcoming quarterly call are high information-density events — misses would likely force downward guidance revisions within a single quarter and create sharp downside given product concentration; conversely, a clean repeat of accelerating scripts materially de-risks the cash-runway narrative over 6–12 months. CMC/manufacturing scaling, formulary placement and rebate dynamics are plausible shock vectors that can flip the trade within 30–90 days.

From a competitive standpoint, a rapid commercial ramp forces incumbents in the gastro space to respond on pricing and formulary tactics, increasing short-term discounting but also creating a moat if PHAT secures preferred placement; that dynamic favors well-capitalized commercial partners or an acquirer with existing GI channel access. Watch capacity and working-capital signals from CMO counterparties — rising AP/inventory in vendor filings is an early warning that growth is straining execution.

Consensus is long momentum and underweights execution risk. Positioning that assumes linear prescription growth is the vulnerable narrative: a single weak IQV weekly release or negative payer decision can erase a large fraction of the implied upside. Conversely, if scripts sustain for two consecutive quarters, upside is likely underpriced because market participants will re-rate the stock from a growth-at-risk multiple to a growth-conversion multiple within 6–12 months.

Key Decisions for Investors

• Directional options spread (PHAT): Buy the Jan-2027 15/30 call vertical (debit spread). Rationale: asymmetric upside if scripts and H2 sales accelerate; max loss = premium paid, max gain = spread width minus premium. Timeframe: 9–12 months; target 2.5x return if the company demonstrates durable sequential script growth by Q2–Q3 results.
• Buy stock + hedge (PHAT): Accumulate shares size-limited to 1–2% of portfolio and buy a 3–6 month 10–15% OTM protective put to cap downside. Rationale: capture near-term momentum while limiting tail loss from a guidance reset around next quarterly release. Timeframe: 1–3 months to reassess after two IQV weekly data prints; acceptable downside 10–15% with >1.5x upside if catalysts clear.
• Pair trade to isolate idiosyncratic risk: Long PHAT equal-notional / Short IBB (biotech ETF) to neutralize sector beta. Rationale: preserves exposure to PHAT’s idiosyncratic execution story while hedging broad-sector risk from macro-driven derisking. Timeframe: 3–6 months, close or rebalance after earnings and two IQV weekly releases.
• Event-driven small-size tactical (IQV): Buy short-dated (1–2 month) calls on IQV ahead of next IQV weekly script release or catalyst windows to capture upside from positive data visibility. Rationale: IQV benefits even if PHAT still under execution, and a positive data print reduces uncertainty for PHAT holders. Risk: short-dated options expire worthless on noisy/mixed prints; size accordingly.